| Name | Dazostinag disodium |
| Description | Dazostinag disodium (TAK-676) is a synthetic novel interferon gene (STING) agonist that triggers STING signaling pathway activation and type I interferon activation. Dazostinag disodium (TAK-676) is also a highly effective immune system modulator with complete resolution and lasting memory of T cell immunity and the ability to promote lasting interferon-dependent anti-tumor immune responses. |
| In vitro | METHODS: The ability of TAK-676 to activate the STING pathway was evaluated in human THP1-Dual and mouse CT26 cells treated with dazostinag disodium (TAK-676) (1.1, 3.3, 10 μM, 2 hours).
RESULTS Expression of pSTING (S366), pTBK1 (S172), and pIRF3 (S396) was dose-dependently induced in both mouse and human cell lines. [1] |
| In vivo | METHODS: Mice were injected subcutaneously into the right flank with CT26, WT tumor cells, A20 tumor cells, or B16F10 tumor cells, and Dazostinag disodium (TAK-676) (0.3, 1.0, 2.0 mg/kg, intravenously, once every three days, 3 times), and the effects on tumor growth were evaluated by measuring growth rate inhibition (GRI) and tumor regression.
RESULTS When Dazostinag disodium (TAK-676) was administered at a dose of 1 mg/kg, BALB/c mice bearing A20 syngeneic tumors showed significant antitumor activity compared to vehicle treatment (GRI 72%, P < 0.001); similar to the A20 tumor model, CT26 tumor-bearing animals treated with 1 mg/kg of Dazostinag disodium (TAK-676) also showed tumor control over vehicle-treated animals; when the dose of Dazostinag disodium (TAK-676) was increased from 1.0 to 2.0 mg/kg, the antitumor activity was significantly increased in both the A20 (GRI=91%, P < 0.001) and CT26 (GRI=132%, P < 0.001) models. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (331.35 mM)
|
| Keywords | TAK-676 | TAK676 | TAK 676 | STING | Dazostinag disodium | Dazostinag |
| Inhibitors Related | 2',3'-cGAMP sodium | SR-717 | ChX710 | STING ligand-1 | STING agonist-4 | SN-008 | diABZI STING agonist-1 | Cridanimod | C-176 | CCCP | diABZI STING agonist-1 trihydrochloride | C-178 |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
